DT&CRO CO., Ltd. (KOSDAQ:383930)
South Korea · Delayed Price · Currency is KRW 1,848.00
+9.00 (0.49%)
At close: Aug 11, 2026
DT&CRO CO. Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 47,768 | 47,747 | 35,971 | 26,586 | 44,008 | 32,749 |
Revenue Growth | 20.94% | 32.74% | 35.30% | -39.59% | 34.38% | 63.02% |
Gross Profit Gross Profit Growth | 2,669 | 2,555 | -3,150 | -6,769 | 8,939 | 7,512 |
Operating Income Operating Income Growth | -5,947 | -5,819 | -7,155 | -16,495 | 5,294 | 4,907 |
Net Income Net Income Growth | -12,281 | -2,777 | -1,999 | -16,636 | 5,256 | 4,328 |
Earnings Per Share EPS Growth | -1202.70 | -393.00 | -157.00 | -1311.00 | 517.00 | 1031.00 |
EPS Growth | - | - | - | - | -49.85% | - |
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Safety Safety Growth | 14,336 | 13,848 | 15,147 | 13,944 | 8,864 |
Clinical Clinical Growth | 11,660 | 3,617 | 18,327 | 15,133 | 10,999 |
Analysis Analysis Growth | 7,002 | 6,467 | 8,006 | 1,924 | 225.32 |
Efficacy Efficacy Growth | 2,973 | 2,654 | 2,528 | 1,748 | - |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 3,521 | 539.44 | 4,943 | 5,533 | 20,526 | 7,074 |
Total Debt Total Debt Growth | 38,979 | 36,056 | 27,925 | 15,881 | 4,887 | 4,840 |
Net Cash (Debt) Net Cash Growth | -35,458 | -35,517 | -22,982 | -10,348 | 15,639 | 2,234 |
Net Cash Growth | - | - | - | - | 599.94% | 191.37% |
Net Cash Per Share Net Cash Per Share Growth | -2772.87 | -2375.84 | -1804.80 | -815.48 | 1538.41 | 532.30 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -1,251 | -2,257 | -6,395 | -3,515 | 5,007 | 6,056 |
Capital Expenditures CapEx Growth | -4,936 | -10,136 | -18,194 | -16,914 | -14,838 | -7,468 |
Free Cash Flow Free Cash Flow Growth | -6,187 | -12,393 | -24,590 | -20,430 | -9,831 | -1,412 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 5.59% | 5.35% | -8.76% | -25.46% | 20.31% | 22.94% |
Operating Margin | -12.45% | -12.19% | -19.89% | -62.04% | 12.03% | 14.98% |
Pretax Margin | -25.09% | -5.19% | -4.28% | -65.10% | 12.02% | 13.30% |
Profit Margin | -25.71% | -5.82% | -5.56% | -62.57% | 11.94% | 13.21% |
FCF Margin | -12.95% | -25.96% | -68.36% | -76.84% | -22.34% | -4.31% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 10.83 | - |
PS Ratio | 0.49 | 0.69 | 2.06 | 8.68 | 1.29 | - |